SUMMARY
Introduction: Characteristic attributes of renal cell carcinoma (RCC) are chemoresistance, radioresistance and strong resistance to immunotherapy. Nephrectomy remains still important part of the therapy mainly in the case of localized carcinoma. Targeted medicament therapy brings new possibilities to progressive and metastatic renal carcinoma therapy.
Aim: The aim of this study was to analyze the results of pharmacotherapy of patients whose underwent targeted therapy in the period of years 2013 to 2018 in oncological ambulance in Bardejov.
Material and methods: The analyzed group comprised 30 patients. The obtained data on age and sex composition of patients, risk factors, comorbidities, method of diagnosis, histological subtype of cancer, presence of metastases, pharmacotherapy, incidence of side effects and duration of treatment were processed using MS Office package.
Results: All patients at the study were older than 45 years. Only 11 patients were non-smokers. Up-to 21 patients had high BMI, from overweight to extremely obesity. Hypertension was the most frequent comorbidity (70 %). Up-to 21 patients underwent nephrectomy. In 29 patients remote metastasis were formed. At first line of the therapy, tyrosine kinase inhibitor sunitinib was the most frequently used drug (73.3 %), followed by pazopanib (26.7 %). Second therapy line was applied in 7, third in 2 patients. The most frequent undesirable effects were weariness and weakness (66.7 %), oral disorders (50 %) and hypertension (40 %). 19 patients died during the therapy, which endured at average about 29 months.
Conclusion: In spite of the improvements in the RCC therapy and availability of wide variety of therapeutics, the effect of the targeted RCC therapy remains unsatisfactory. New generations of targeted therapeutics are promising for the future, but it is always true that the most effective method in the fight against kidney cancer is primary and secondary prevention.
Key words: renal cells carcinoma, targeted therapy, tyrosine kinase inhibitors, sunitinib, pazopanib.
Mária KOLESÁROVÁ 1, Denisa DERCOVÁ 1, Jozef CHOVANEC 2, Hedviga KOŠUTHOVÁ 1,3
1 Katedra farmakológie a toxikológie, Univerzita veterinárskeho lekárstva a farmácie, Košice, vedúci prof. MVDr. J. Legáth, CSc.
2 Onkologická ambulancia NsP Sv. Jakuba, n. o., Bardejov
3 Združená tkanivová banka, Lekárska fakulta, Univerzita Pavla Jozefa Šafárika v Košiciach, prednosta MVDr. J. Rosocha, CSc.
Citácia:
KOLESÁROVÁ M., DERCOVÁ D., CHOVANEC J., KOŠUTHOVÁ H.: Targeted Therapy for locally Advanced and Metastatic Kidney Cancer. Lek Obz, 2021, 70 (3): 92-100
